Total Payments
$9,102
2024 Payments
$1,258
Companies
30
Transactions
391
Medicare Patients
2,307
Medicare Billing
$279,908
Payment Breakdown by Category
Food & Beverage$8,724 (95.8%)
Other$371.70 (4.1%)
Education$6.80 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,724 | 388 | 95.8% |
| Debt forgiveness | $371.70 | 2 | 4.1% |
| Education | $6.80 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,728 | 78 | $0 (2024) |
| ABBVIE INC. | $1,385 | 57 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $644.90 | 32 | $0 (2024) |
| Radius Health, Inc. | $537.72 | 28 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $533.11 | 20 | $0 (2024) |
| Lilly USA, LLC | $523.58 | 23 | $0 (2024) |
| Astellas Pharma US Inc | $453.14 | 21 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $429.36 | 22 | $0 (2024) |
| GlaxoSmithKline, LLC. | $379.49 | 18 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $321.93 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,258 | 51 | Novo Nordisk Inc ($301.42) |
| 2023 | $1,733 | 79 | ABBVIE INC. ($598.55) |
| 2022 | $2,052 | 88 | ABBVIE INC. ($479.17) |
| 2021 | $1,903 | 83 | Novo Nordisk Inc ($569.76) |
| 2020 | $989.20 | 52 | Novo Nordisk Inc ($235.51) |
| 2019 | $276.18 | 11 | Novo Nordisk Inc ($92.61) |
| 2018 | $324.20 | 11 | Allergan Inc. ($96.00) |
| 2017 | $567.01 | 16 | AstraZeneca Pharmaceuticals LP ($156.03) |
All Payment Transactions
391 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $9.62 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: PAIN | ||||||
| 10/30/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Diabetes | ||||||
| 10/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.59 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $21.28 | General |
| Category: Opioid Analgesic | ||||||
| 10/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: Cardio-renal | ||||||
| 10/04/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Endocrinology | ||||||
| 10/02/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: RESPIRATORY | ||||||
| 09/25/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $107.58 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/17/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: NEUROSCIENCE | ||||||
| 09/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.26 | General |
| Category: Diabetes | ||||||
| 09/04/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $22.13 | General |
| Category: Opioid Analgesic | ||||||
| 09/03/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Biological | ||||||
| 08/27/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: VACCINE | ||||||
| 08/26/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: Diabetes | ||||||
| 08/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $34.91 | General |
| Category: NEUROSCIENCE | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: RESPIRATORY | ||||||
| 08/20/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Diabetes | ||||||
| 08/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.44 | General |
| Category: DIABETES | ||||||
| 07/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Diabetes | ||||||
| 07/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.55 | General |
| Category: NEUROSCIENCE | ||||||
| 07/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Cardio-renal | ||||||
| 07/09/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $106.47 | General |
| 07/08/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 529 | 939 | $145,074 | $50,307 |
| 2022 | 18 | 873 | 3,264 | $378,292 | $142,888 |
| 2021 | 13 | 440 | 720 | $92,980 | $44,341 |
| 2020 | 13 | 465 | 783 | $73,495 | $42,372 |
Total Patients
2,307
Total Services
5,706
Medicare Billing
$279,908
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 131 | 335 | $64,350 | $22,461 | 34.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 65 | $10,900 | $4,276 | 39.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 59 | 95 | $15,875 | $4,095 | 25.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 22 | 93 | $12,450 | $3,805 | 30.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 22 | 32 | $5,200 | $3,074 | 59.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $5,400 | $2,282 | 42.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 21 | $4,910 | $2,266 | 46.2% |
| 99348 | Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 25 | 33 | $7,175 | $1,668 | 23.2% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 38 | 75 | $4,500 | $1,418 | 31.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 19 | 19 | $2,050 | $1,363 | 66.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 12 | $2,925 | $1,271 | 43.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 38 | 38 | $2,850 | $840.80 | 29.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 28 | 28 | $560.00 | $548.80 | 98.0% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 38 | 38 | $3,154 | $541.02 | 17.2% |
| 99484 | Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | Office | 2023 | 37 | 37 | $2,775 | $398.33 | 14.4% |
| 99489 | Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 91 | 771 | $89,088 | $32,667 | 36.7% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 92 | 394 | $87,074 | $29,991 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 111 | 248 | $37,200 | $17,261 | 46.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 116 | 491 | $40,753 | $12,472 | 30.6% |
| 99484 | Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | Office | 2022 | 117 | 497 | $37,267 | $12,311 | 33.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 87 | 158 | $19,750 | $6,959 | 35.2% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 26 | 230 | $13,740 | $6,760 | 49.2% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 29 | 125 | $12,875 | $5,181 | 40.2% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 11 | 58 | $7,250 | $3,020 | 41.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 44 | $6,600 | $2,629 | 39.8% |
About Dr. Kent Matsuda, M.D
Dr. Kent Matsuda, M.D is a Internal Medicine healthcare provider based in Santa Rosa, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073531117.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kent Matsuda, M.D has received a total of $9,102 in payments from pharmaceutical and medical device companies, with $1,258 received in 2024. These payments were reported across 391 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($8,724).
As a Medicare-enrolled provider, Matsuda has provided services to 2,307 Medicare beneficiaries, totaling 5,706 services with total Medicare billing of $279,908. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Santa Rosa, CA
- Active Since 07/17/2006
- Last Updated 05/19/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1073531117
Products in Payments
- Ozempic (Drug) $1,058
- VRAYLAR (Drug) $991.77
- Kerendia (Drug) $533.11
- JARDIANCE (Drug) $502.32
- Tymlos (Biological) $437.36
- TRELEGY ELLIPTA (Drug) $357.88
- Rybelsus (Drug) $302.44
- Belbuca (Drug) $292.42
- UBRELVY (Drug) $285.76
- QULIPTA (Drug) $279.17
- MYRBETRIQ (Drug) $223.25
- EMGALITY (Drug) $201.49
- None (Device) $185.85
- ENTRESTO (Drug) $157.18
- MOVANTIK (Drug) $156.03
- AMYVID (Drug) $144.68
- XTAMPZA (Drug) $136.94
- Myrbetriq (Drug) $130.87
- XIFAXAN (Drug) $128.88
- FARXIGA (Drug) $128.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Santa Rosa
Zeyad Kanaan, M.d, M.D
Internal Medicine — Payments: $230,599
Internal Medicine $230,599
Rajveer Sangera, Do, DO
Internal Medicine — Payments: $42,357
Internal Medicine $42,357
Pamela Maur, M.d, M.D
Internal Medicine — Payments: $41,731
Internal Medicine $41,731
Dr. Marlon Decastro, M.d, M.D
Internal Medicine — Payments: $7,445
Internal Medicine $7,445
Sara Keck, Md, MD
Internal Medicine — Payments: $7,051
Internal Medicine $7,051
Neil Levin, M.d, M.D
Internal Medicine — Payments: $6,990
Internal Medicine $6,990